NCT03201471 (DLBCL) is a Phase 2 clinical trial of Chidamide + R-CHOP regimen in Diffuse Large B Cell Lymphoma, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT03201471?

NCT03201471 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT03201471?

Interventions in NCT03201471: Chidamide + R-CHOP regimen.

What condition does NCT03201471 study?

NCT03201471 studies Diffuse Large B Cell Lymphoma.

Is NCT03201471 still recruiting?

NCT03201471 is currently status unknown. Last updated 2 August 2018.

Last reviewed 2018-08-02 · How we verify

NCT03201471: DLBCL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chidamide With R-CHOP Regimen for DLBCL Patients

Status unknown Phase 2 Last updated 2 August 2018

What this trial tests

Phase 2 trial testing Chidamide + R-CHOP regimen in Diffuse Large B Cell Lymphoma in 39 participants. Status unknown.

Timeline

20 August 2017

Primary endpoint
30 December 2019

5 February 2020

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	20 August 2017
Primary completion	30 December 2019
Estimated completion	5 February 2020
Sites	1 location across China

Drugs / interventions tested

Chidamide + R-CHOP regimen — full drug profile →

Conditions studied

Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Adults 18 to 75, any sex, with Diffuse Large B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It's a prospective, single arm, open label phase II clinical trial, in which the safety and efficacy of Chidamide plus R-CHOP regimen is accessed in de novo DLBCL patients, who have received 2 courses of R-CHOP but only achieved PR or whose MRD tests for ctDNA revealed positive results. abbreviation: R-CHOP: the chemo-therapy regimen composed of Rituximab, cyclophosphoamide, etoposide, vincristine and prednisone. PR: partial remission; MRD:minimal residual disease;

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

New agents and regimens for diffuse large B cell lymphoma.
Wang L, Li LR, Young KH. · · 2020 · cited 109× · PMID 33317571 · DOI 10.1186/s13045-020-01011-z
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2
Recent Update of HDAC Inhibitors in Lymphoma.
Chen IC, Sethy B, Liou JP. · · 2020 · cited 60× · PMID 33015069 · DOI 10.3389/fcell.2020.576391
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
Immune targeted therapy for diffuse large B cell lymphoma.
Zheng Y, Si J, Yuan T, Ding S, et al · · 2021 · cited 6× · PMID 35402846 · DOI 10.1097/bs9.0000000000000095

Verify or expand the search:

Other recruiting trials for Diffuse Large B Cell Lymphoma

Currently open trials in the same condition.

NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03201471 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 2 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03201471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing